Phaseline

Companies › FBD Biologics

FBD Biologics: clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HCB301
Engineered SIRPα fused to anti-PD-L1 and TGF-β fusion protein
SIRPA, PDCD1LG2, TGFB1Phase 1Advanced Solid TumorDec 2026
HCB101
SIRPα-Fc fusion protein targeting CD47
SIRPA, CD47Phase 1Advanced Solid Tumor; Solid Cancer; CRC; HNSCCMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07204574HCB101Phase 1CRCOncologyDec 2025
NCT06487624HCB301Phase 1Advanced Solid TumorOncologyDec 2026
NCT07136545HCB101Phase 1HNSCCOncologyDec 2026
NCT05892718HCB101Phase 1Advanced Solid TumorOncologyMay 2027
NCT06771622HCB101Phase 1Solid CancerOncologyJan 2028

Targets

SIRPA (2) PDCD1LG2 (1) TGFB1 (1) CD47 (1)

Companies with the same targets

Pfizer Bristol-Myers Squibb Phanes Therapeutics Sairopa Electra Therapeutics Kahr Medical Byondis Biotheus Boehringer Ingelheim GSK

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.